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Themechanism of action of arsenic trioxide (ATO) has been shown to be complex, influencing numerous signal trans-
duction pathways and resulting in a vast range of cellular effects. Among these mechanisms of action, ATO has been
shown to cause acute vascular shutdown and massive tumor necrosis in a murine solid tumor model like vascular
disrupting agent (VDA). However, relatively little is understood about this VDA-like property and its potential utility in
developing clinical regimens. We focused on this VDA-like action of ATO. On the basis of the endothelial cell cyto-
toxicity assay and tubulin polymerization assay, we observed that higher concentrations and longer treatment with
ATO reduced the level of α- and β-tubulin and inhibited the polymerization of tubulin. The antitumor action and quan-
titative tumor perfusion studies were carried out with locally advanced murine CT26 colon carcinoma grown in female
BALB/cmice. A single injection of ATO intraperitoneally displayed central necrosis of the tumor tissue by 24 hours. T1-
weighted dynamic contrast-enhanced magnetic resonance image revealed a significant decrease in tumor enhance-
ment in the ATO-treated group. Similar to other VDAs, ATO treatment alone did not delay the progression of tumor
growth; however, ATO treatment after injection of other cytotoxic agent (irinotecan) showed significant additive anti-
tumor effect compared to control and irinotecan alone therapy. In summary, our data demonstrated that ATO acts as a
VDA by means of microtubule depolymerization. It exhibits significant vascular shutdown activity in CT26 allograft
model and enhances antitumor activity when used in combination with another cytotoxic chemotherapeutic agent.
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Because of their significant medicinal properties, naturally occurring
arsenic compounds have been used to treat various diseases for more
than 2400 years. Arsenic compounds became a therapeutic mainstay
for various ailments in the 19th and early 20th centuries, particularly
in the Far East as part of traditional Chinese medicine. For example,
arsenic trioxide (As2O3, ATO) was used as one of the standard treat-
ments for leukemia until the introduction of chemotherapy and radia-
tion therapies in the mid-1900s. However, as medicine evolved in the
early 20th century and as the toxic and oncogenic effects of arsenic
became apparent, enthusiasm for medicinal arsenic waned rapidly and
therapeutic use was eventually abandoned [1].
After the 1970s, ATO was reintroduced as an anticancer agent
after reports described complete remission of acute promyelocytic
leukemia (APL). After randomized multicenter clinical trials, ATO
was approved by the U.S. Food and Drug Administration for the treat-
ment of relapsed or refractory APL in September 2000 [2,3]. Notably,
the apoptotic effects of ATO are not restricted to APL but have been
observed in other malignancies, including myeloma, chronic myeloid
leukemia, and various solid tumors such as prostate, esophageal, and
ovarian carcinomas [4].
So far, the mechanism of action of ATO has been shown to be com-
plex, influencing numerous signal transduction pathways and resulting
in a vast range of cellular effects that include apoptosis induction,
growth inhibition, promotion, or inhibition of differentiation and in-
hibition of angiogenesis [5]. Similar to effects observed in vascular dis-
rupting agent (VDA), ATO has been shown to cause acute vascular
shutdown and massive tumor necrosis in a murine solid tumor model
[6]. Although there have been numerous reports in the literature about
the mechanism of action of ATO, relatively little is understood about
this VDA-like property and its potential utility in developing clinical
regimens [1,4,5].
In this study, we reconfirm the vascular disrupting effects of ATO
in CT26 allograft mice by quantitative analysis of dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI). The vascular
disrupting effect of ATO is shown to have limited effects on tumor-
specific vessels attributable to the morphologic change of vascular
endothelial cells by cytoskeleton-associated protein degradation of
tubulin. In addition, our results indicate that ATO as a VDA, in com-
bination with irinotecan, enhances antitumor activity in CT26 allo-
graft mice.Materials and Methods
Cell Culture and Reagents
Human umbilical vein endothelial cells (HUVECs) were pur-
chased from the American Type Culture Collection (ATCC,Manassas,
VA) and maintained in Ham’s Kaighn’s Modification F12 (F12K;
Invitrogen, Carlsbad, CA) supplemented with 2 mM L-glutamine
(Invitrogen), 0.1 mg/ml heparin sodium salt from porcine intestinal
mucosa (Sigma-Aldrich, St Louis, MO), 0.05 mg/ml endothelial cell
growth supplement (BD Pharmingen, Franklin Lakes, NJ), and 10%
fetal bovine serum (Invitrogen). This medium was prepared fresh every
2 weeks. The murine CT26 colon carcinoma cell line (ATCC) was
routinely maintained in RPMI 1640 medium supplemented with
10% fetal bovine serum. ATO (Sigma-Aldrich) was dissolved in 1 M
NaOH as a stock solution. Paclitaxel was donated from BMS Pharma-
ceutical Korea (Seoul, Korea), and a stock solution of paclitaxel wasprepared as a manufactured supplement. Vincristine was donated by
Reyon Pharmaceutical (Seoul, Korea) and was prepared at a 0.1 M
concentration in phosphate-buffered saline (PBS). Irinotecan (Sigma-
Aldrich) was prepared at a 0.1 M concentration in PBS.MTS Cell Proliferation Assay
The CellTiter 96 AQueous One Solution Assay (Promega, Madison,
WI) is a colorimetric method for determining the number of viable
cells in proliferation or cytotoxicity assays. The One Solution contains
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt] and an electron coupling
reagent (phenazine ethosulfate). The MTS is bioreduced by cells into
a colored formazan product that is soluble in tissue culture medium.
The quantity of formazan product as measured by the amount of
490-nm absorbance is directly proportional to the number of living
cells in culture. Serum-starved HUVECs (3 × 103 cells per well, cul-
tured during 24 hours on a 96-well plate) were treated with ATO
(0–100 μM) for 24 and 48 hours. Following ATO treatment, the cells
were incubated for 4 hours at 37°C after 20 μl of MTS reagent was
added to 100 μl of fresh culture medium in each well. The absorbance
at 490 nm was recorded using an ELISA plate reader (EL800; BioTek,
Winooski, VT). The percentage of absorbance was calculated against
untreated control cells. Percent proliferation = (absorbance of experi-
mental well/absorbance of control well) × 100.Flow Cytometric Analysis of Annexin V–Fluorescein
Isothiocyanate Staining
Annexin V–fluorescein isothiocyanate (FITC) staining was performed
using FITC Annexin V Apoptosis Detection Kit (BD Biosciences,
Franklin Lakes, NJ) according to the manufacturer’s instructions.
HUVECs (2 × 106 cells) were treated with ATO at the indicated con-
centration for 24 to 48 hours. Cells were washed twice with cold PBS
by spinning at 1000 rpm for 5 minutes at 4°C. The cell pellet was
resuspended in ice-cold diluted binding buffer to 5 × 105 to 5 ×
106 cells/ml. The tubes were kept on ice, and 1 μl of annexin V–FITC
solution was added to 100 μl of the cell suspension. Following a
10-minute incubation period at 4°C in the dark, 400 μl of binding
buffer (0.1 M Hepes, pH 7.4; 1.4 M NaCl; 25 mM CaCl2) was added
to each tube, which were then analyzed by flow cytometry using a
FACSCalibur flow cytometer and Cell Quest software (BD Biosciences).Tubulin Polymerization Assay
Cells were plated onto 24-well plates, grown for 1 day (reaching
60–80% confluency), and treated with 5 and 10 μM ATO at 37°C
for 6 hours. Cells with no drug added were used as the control. After
the media was removed, cells were rinsed in 1× PBS at 22°C and har-
vested at the same temperature in lysis buffer containing 0.1 M Pipes,
1 mM EGTA, 1 mM MgSO4, 30% glycerol, 5% DMSO, 5 mM
GTP, 0.125% NP-40, and a protease inhibitor cocktail (Calbiochem,
Merck KGaA, Darmstadt, Germany). The mixture was then centri-
fuged at 13,200 rpm at 22°C for 30 minutes, followed by vortexing to
separate the polymerized (P) tubulin from the soluble (S) tubulin.
This procedure and subsequent modifications have been widely used
and allow for a quick and consistent assessment of the proportion of
tubulin polymer in cells under a variety of experimental conditions [7].
Pellets of P and S tubulin were resuspended in lysis buffer. Gel sample
buffer was added to each sample, and equal aliquots were separated
by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
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membrane (Bio-Rad, Hercules, CA), immunoblot analysis was per-
formed with anti–α-tubulin (Santa Cruz Biotechnology, Santa Cruz,
CA), followed by goat anti-mouse IgG secondary antibody (Santa Cruz
Biotechnology) conjugated to horseradish peroxidase with a mono-
clonal antibody against glycealdehyde-3-phosphate dehydrogenase as
a loading control.
Immunoblots
HUVECs grown to 70% to 80% confluency in F25 culture flask
were harvested after drug treatment in 100 μl/well protein lysis buffer
containing 50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, complete protease inhibitor cocktailFigure 1. ATO-induced cytotoxicity and apoptosis of HUVECs. (A) Tim
Cell cytotoxicity was assessed by MTS assay. (B) Fluorescence-activ
concentrations for 24 and 48 hours. Percentage of annexin V-FITC ptablets (Roche, Basel, Switzerland), 200 U/ml aprotinin (Sigma-Aldrich),
and 10 μM trichostatin A (Cayman Chemical, Ann Arbor, MI). Protein
concentrations were determined using the Bio-Rad Protein Assay
Reagent (Bio-Rad), and 3 μg of protein was loaded into each well
and resolved using 10% SDS-PAGE. After protein transfer onto nitro-
cellulose, blots were blocked using 5% milk, and each blot was probed
with an anti–glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz
Biotechnology) as an internal control. Other primary antibodies used
were anti–α-tubulin and anti–β-tubulin (Santa Cruz Biotechnology),
and the membrane was introduced to goat anti-mouse IgG secondary
antibody (Santa Cruz Biotechnology) conjugated to horseradish
peroxidase and exposed to light with Molecular Imager ChemiDoc
XRS (BioRad) using Immun-Star.e- and concentration-dependent cytotoxicity of HUVECs by ATO.
ated cell sorting analysis of HUVECs treated with ATO at indicated
ositive cells was reported (*P < .05).
Figure 2. ATO induces depolymerization of microtubules in HUVECs. (A) HUVECs were treated with ATO or no drug (control), for
24 hours at the indicated concentrations. Cell lysates were separated into P and S fractions by centrifugation at 2000 rpm at 22°C
for 30 minutes. Equal volumes were separated by SDS-PAGE and evaluated by immunoblot and probed with anti–α-tubulin. (B) Repre-
sentative densitometric analysis showing relative protein level of each fraction. Values are mean ± SD of three independent experiments
(*P < .05 compared to 0 μM). (C) Confocal imaging of microtubules from HUVECs treated with ATO (5 and 10 μM), paclitaxel, and
vincristine for 24 hours.
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After the cultivation of HUVECs on the confocal dish (SPL Life-
science, Pocheon, Korea) for 24 hours, the cells were treated with 5
and 10 μMATO. At 24 and 48 hours after the treatment, the cells were
fixed with 3.7% paraformaldehyde at room temperature for 10 minutes.
After being washed with PBS solution three times, the cells were treated
with 0.15% Triton X-100 for 15 minutes and washed three times with
PBS. After being blocked with 2% bovine serum albumin (Sigma-
Aldrich) at room temperature for 60 minutes, the cells were washed
three times with the PBS. Monoclonal antibody against α-tubulin
(Santa Cruz Biotechnology) was used to react with cell tubulin at room
temperature for 1 hour, and the cells were washed three times with
PBS. They were then exposed to rat anti-mouse IgG1 secondary anti-
body (BD Biosciences) conjugated to FITC. After being washed three
times with PBS, the cells were analyzed by using a model FV500 con-
focal laser scanning microscope (Olympus, Tokyo, Japan).
Animal and Tumor Model
All research protocols were governed by the principles of the Guide
for the Care and Use of Laboratory Animals and approved by the Uni-
versity of Ulsan Institutional Animal Care and Use Committee. Female
BALB/c mice (6–8 weeks of age) were obtained from ORIENTBIO
(Seoul, Korea) and maintained under specific pathogen-free conditions.
A murine CT26 colon carcinoma cell suspension (1 × 106 cells in 100 μl
of PBS) was injected subcutaneously on the right upper quadrant of
abdomen or on the right hind limbs of the mice for the study ofDCE-MRI. Tumors were allowed to grow for approximately 7
to 14 days, until reaching a predetermined size, the longest diameter
of which ranged from 0.6 to 2 cm.
Tumor Perfusion Measurement with DCE-MRI
All MRI examinations were performed using a 3-Tesla human
clinical magnetic resonance imaging system (Achieva; Philips Health-
care, Best, The Netherlands) with a mouse coil that has a 4-cm inner
diameter. When the tumor size became 1 cm in diameter, pretreatment
baseline MRI images were obtained (8 days after tumor cell injection).
Then, each group was treated intraperitoneally with 100 μl of ATO at a
concentration of 7.5 mg/kg or sham injections of 100 μl of saline. Post-
treatment MRI was performed 24 hours after treatment. All images were
obtained under inhaled anesthesia with 1.5% isoflurane in 100% oxygen
at a flow rate of 1 l/min. Mice were placed prone in a plastic holder for
ease of fixation and injection of contrast agent, and the tail vein was
cannulated for intravenous injection of gadolinium contrast agent. After
precontrast images were taken, an intravenous bolus of gadopentetate
dimeglumine (Magnevist; Schering, Erlangen, Germany) was adminis-
tered by manual injection at a dose of 281 mg/kg over a maximum
period of 5 seconds, and then postcontrast images were obtained.
For DCE-MRI scan, gadopentetate dimeglumine was administrated
at a dose of 281 mg/kg through tail vein injection. DCE-MRI was
performed using a spin echo sequence using the following acquisition
parameters: FOV (field of view, mm) = 50 × 35, RFOV (rectangular
FOV, %) = 70, TR/TE (repetition time/echo time, ms) = 12/4.0,
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total acquisition time of 2 minutes and 6 seconds. Raw data were
transferred to a processing workstation and converted into analyze
format. PRIDE tool (Philips Healthcare) was used for fitting dynamic
data. The data were analyzed by BRIX model method ( J Comput Assist
Tomogr 15(4), 621–628).
Histopathologic Staining
CT26 cells were harvested from monoconfluent monolayer cell cul-
tures, and 2 × 106 cells in a total volume of 100 μl of PBS were injected
subcutaneously. When the tumor size became 3 mm in diameter, the
control group was injected with PBS solution with 5% dextrose, whereas
the experimental group was intraperitoneally injected with 100 μl of
ATO at a concentration of 7.5 mg/kg with 5% dextrose. At 8, 24,
and 48 hours after injection, the liver, spleen, and tumor tissues were
acquired and put into a 37% solution of formaldehyde for 24 hours.
The tissues were inserted into paraffin and sectioned at a thickness
of 4 μm using a microtome (SLEEMedical GmbH, Mainz, Germany).
The sections were placed on the slides and stained with Mayer’s hema-
toxylin and eosin (both from Sigma-Aldrich). Images were observed
using a model BX50 inverted microscope (Olympus).
Antitumor Activity
Antitumor effects of irinotecan and ATO were evaluated in the
mouse CT26 allograft model. Female BALB/c mice weighing approx-Figure 3. Gross morphologic and histopathologic changes. (A) Necr
Histologic analysis of tumor and normal tissues treated with ATO (
zone; N, necrotic zone).imately 20 g were inoculated by subcutaneous injection with 2 × 106 of
CT26 cells per mouse. When tumor size became 3 mm in diameter, the
control group was injected weekly with PBS containing 5% dextrose.
The experimental groups were randomized into different treatment
groups: irinotecan alone (15 mg/kg/week with 5% dextrose), ATO
alone (7.5 mg/kg/week with 5% dextrose), and irinotecan (15 mg/kg)
combined with ATO (7.5 mg/kg). All experiment groups were treated
weekly for 4 weeks. Mice were monitored for toxicity by body weight
measurements, and tumor growth was measured once every 2 days
using calipers throughout the experimental period. Tumor volumes
were calculated on the basis of the following formula: tumor volume =
(length × width2) × π/6.
Statistical Analysis
The results obtained from at least three independent experiments
were expressed as mean ± SD. One-way analysis of variance tests were
used to determine the differences between control and treatment
groups. P < .05 was considered to be statistically significant.
Results
ATO-induced Cytotoxicity and Apoptosis of HUVECs
To investigate the effect of ATO on vascular endothelial cells, HUVECs
were treated with different concentrations of ATO, and cytotoxicity was
determined by the MTS assay. At 20 μM or more, ATO exposure forosis in tumor after treatment of ATO in CT26 allograft model. (B)
tumor stained with hematoxylin and eosin; V, non-necrotic viable
Figure 4. Quantitative analysis of the DCE-MRI parameter in CT26 allograft model. (A) T1-weighted gadolinium contrast-enhanced MRI
of pretreatment and 24-hour posttreatment. Arrows indicate enhancing tumors at the proximal hind leg of the mice. (B) The change in
Kep for each animal treated with ATO or saline. (C) Changes in the mean values of Kep measured before treatment and 24 hours post-
treatment (*P < .05).
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whereas 48 hours of exposure decreased cell viability to under 30%. Cyto-
toxicity was proportional to both time and concentration (Figure 1A). To
show whether the cytotoxicity by ATO was caused by induction of apop-
tosis, annexin V–FITC fluorescence-activated cell sorting analysis was
used after treatment of HUVECs with ATO. Annexin V–FITC positive
cells were significantly increased at treatment doses of 10 μM or more,
and this was especially apparent with prolonged treatment (Figure 1B).Figure 5. ATO treatment alone has a no inhibitory effect on tu-
mor in CT26 allograft models. Control group mice were injected
intraperitoneally with saline. ATO group mice were injected with
7.5 mg/kg ATO. All experiment groups were treated once weekly
for 4 weeks. Black (ATO) and white (saline) arrowheads indicate
each treatment.ATO Induces Microtubule Depolymerization in HUVECs
To investigate whether apoptosis of HUVECs was caused by a
cytoskeletal abnormality, the change in α-tubulin expression in the
cytoskeleton was identified by the tubulin polymerization assay
separating P from S tubulin. This procedure and subsequent modi-
fications have been widely used and allow a quick and consistent
assessment of the proportion of tubulin polymer in cells under a
variety of experimental conditions. An increase in the S fraction served
as an indicator of destabilized tubulin. As shown in Figure 2, A and B,
higher concentrations of ATO reduced the P fraction significantly com-
pared to the untreated control. Furthermore, the S fraction was also
reduced with increasing concentrations of ATO. These results indicate
that ATO not only promotes tubulin depolymerization but also reduces
the overall amount of tubulin. Because strong tubulin-destabilizing
activity was found in vitro, we tested whether ATO treatment affected
the cellular microtubule network. HUVECs were treated with 4 nM
paclitaxel, 40 nM vincristine, and ATO (5 and 10 μM) with the same
volume of PBS solution as the control (Figure 2C). The microtubule
network in control cells exhibited normal arrangement and organiza-
tion. Treatment with paclitaxel resulted in microtubule polymerizationwith an increase in the density of cellular microtubules and formation
of long thick microtubule bundles surrounding the nucleus. In con-
trast, vincristine treatment caused cellular microtubule depolymeriza-
tion with short microtubules noted in the cytoplasm. Cells treated
with ATO displayed concentration-dependent findings similar to those
of vincristine-induced microtubule changes, such as shortening and
decreased density of microtubules.
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with ATO in CT26 Allograft Model
Figure 3A illustrates the gross tumor morphology before and after a
single injection of ATO. The discoloration of the tumor tissues of
the mice injected without ATO was not observed until day 6; how-
ever, the central part of tumor tissues became ulcerated 1 day after
the injection of ATO. Histopathologic examination of tumor tissues
of the mice who did not receive ATO showed that cell density
remained constant and that the cells were distributed without
any changes in shape. On the contrary, necrotic cell death was evi-
dent in the tumor tissues of mice injected with ATO (Figure 3B).
In kidney and liver tissues, ATO-mediated ischemic damage was
not observed.Quantitative Analysis of the DCE-MRI
After exclusion of experimental animals whose DCE-MRI images
failed to be acquired because of advance enhancement and of mice
whose intravenous injection lines failed to be cannulated, four mice
were treated with ATO and four were treated with saline before DCE-
MRI data collection. As the MRI data were mapped from each result
of both animals treated with saline and animals treated with ATO,
K ep values were calculated. K ep (rate constant) is the back-diffusion
rate constant from interstitial space to vascular space, reflecting leak-
age of tumor vessels (i.e., vascularity). Contrast enhancement of tu-
mor was significantly decreased in the ATO-treated group compared
to that of saline-injected group (Figure 4A). K ep values in the group of
mice treated with saline were not significantly changed; however, K ep
values in mice treated with ATO were significantly reduced (P < .05;
P value for ATO group = .004, for saline group = .659) (Figure 4, B
and C ). This means that vascularity in the ATO-treated group was
significantly reduced after treatment in comparison of the group of
animals treated with the saline.Antitumor Activity of ATO in CT26 Allograft Model
To evaluate the antitumor effects of ATO treatment alone, tumor
growth in CT26 allograft mice treated with ATO (7.5 mg/kg) was
compared with tumor growth in vehicle-treated controls. ATO treat-
ment alone did not delay the progression of tumor growth, suggest-
ing that ATO treatment alone has no inhibitory effect on tumor
growth in the CT26 allograft model (Figure 5).Figure 6. ATO combined with irinotecan has an additive inhibitory
effect in CT26 allograft model. (A) Injection of ATO (black arrow-
head; once weekly) at 30 minutes after injection of irinotecan
(white arrowhead; once weekly). (B) Injection of irinotecan (once
weekly) at 48 hours after injection of ATO (once weekly). (C) Injec-
tion of ATO (twice weekly) at 24 and 72 hours after injection with
irinotecan (once weekly). All groups were treated for 4 weeks.
White (irinotecan) and black (ATO) arrowheads indicate treatment.
Irinotecan and ATO were injected intraperitoneally at concentra-
tions of 10 mg/kg and 7.5 mg/kg, respectively (*P < .05).Irinotecan Combined with ATO Has an Additive Inhibitory
Effect in CT26 Allograft Model
Because irinotecan (CPT-11) is a chemotherapeutic agent widely
used in colorectal cancer with 5-fluorouracil and oxaliplatin, we eval-
uated antitumor effect of these agents in the CT26 allograft model.
We chose irinotecan as a combination partner in this study because
the antitumor effect of irinotecan is the best among these three drugs
(data not shown).
To evaluate the antitumor effects of irinotecan in combina-
tion with ATO, we used three different sequences of administration.
First, we injected ATO with irinotecan simultaneously (Figure 6A);
second, we injected irinotecan once weekly at 48 hours after ATO
injection (Figure 6B); third, we injected ATO twice weekly at 24
and 72 hours after irinotecan injection (Figure 6C ). The result of
each combination therapy was evaluated in comparison with the
result of control and of irinotecan therapy alone. Growth was in-hibited with irinotecan alone compared to the control (Figure 6A,
23.0%; Figure 6B, 23.2%; Figure 6C , 25.0%). Twice weekly ATO
treatment after injection of irinotecan shows significant additive
antitumor effect compared to control and irinotecan alone therapy
(45–56%, P < .05), however, simultaneous injection of ATO with
irinotecan shows no additive effect, and injection of irinotecan 1 day
after injection of ATO shows less suppression of tumor growth
compared to irinotecan alone.Discussion
Our data demonstrate that ATO has a vascular disrupting property
that is caused by the degradation of α- and β-tubulin in microtubules of
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significantly increased tumor growth delay and local tumor control,
apparently without a comparable increase in the reaction of the
normal tissues.
ATO has now been widely studied and used successfully as an
antineoplastic agent. It demonstrates clear activity in anthracycline-
and all-trans retinoic acid–resistant APL. ATO can also be used to
treat acute leukemia, chronic myelogenous and lymphocytic leuke-
mias, myelodysplasia, and multiple myeloma. In addition, ATO is
under investigation as treatment for a variety of solid tumors, includ-
ing bladder cancer, gliomas, breast cancer, hepatocellular carcinoma,
cervical cancer, colorectal cancer, esophageal cancer, germ cell tumors,
liver cancer, lung cancer, and melanoma (www.clinicaltrials.gov). The
mechanisms of apoptosis are attributed to multiple mechanisms,
including bcl-2 down-regulation, caspase 3 activation, tubulin dys-
function, and inhibition of nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB). Although there have been numerous
reports regarding these mechanisms of action, relatively little is known
about the cellular and physiological mechanisms of ATO effect on
solid tumors in vivo, especially with respect to antivascular effects
and appropriate clinical regimen development. Even after a report
that a single dose of ATO was sufficient to induce preferential vascular
shutdown in tumor tissue causing massive necrosis in the central por-
tion of the tumor [6], only a few studies have been published on the
use of this compound as a significant thermosensitizer and radiation
sensitizer of solid tumors [8–12]. In these early studies, the hypothe-
sized mechanism of selective tumor vascular shutdown caused by
ATO is increased adhesion molecule activity, cytokine production,
and cytotoxicity related to mitogen-activated protein kinase activity
in tumor endothelial cells. In other studies, the cytoskeleton has been
suggested as a potential cellular target for ATO because its major
constituent, tubulin, has a relatively high sulfhydryl content [13].
In our study, we focused on this second mechanism of action. Sim-
ilar to other VDAs, ATO can directly affect tubulin. We first observed
that ATO inhibited the polymerization of tubulin in a cell-free system,
which was similar to the effect of colchicine. To further confirm the
results, changes in the cellular microtubule network were observed by
indirect immunofluorescence following exposure to ATO. After treat-
ment with 10 μM ATO for 24 hours, depolymerization of micro-
tubules was observed in HUVECs. This effect is similar to that of
vincristine. These results indicate that ATO has similar effects of other
microtubule depolymerizing agents, including colchicine, podophyllo-
toxin, and vinca alkaloids. The biologic response of tumors to VDA
treatment is typically characterized by early increases in vascular perme-
ability followed by vascular collapse and cessation of blood flow leading
to ischemia and tumor necrosis [14,15].
Among a number of MRI techniques used to investigate anti-
vascular effects, DCE-MRI is the most widely studied, noninvasive,
quantitative method of investigating microvascular structure and func-
tion by tracking the pharmacokinetics of injected low-molecular weight
contrast agents as they pass through the tumor vasculature [16–18].
In this study, T1-weighted DCE-MRI revealed a significant decrease
in tumor enhancement in the ATO-treated group compared to the
saline-injected group.
To date, because of less sensitive tumor peripheral vascular shut-
down, VDAs have failed as single therapeutic agents. This observation
is likely because of interstitial fluid pressure and the vascular architec-
ture of tumor periphery compared to tumor center. It is believed that
peripheral rim of viable cells survives as a result of the diffusion ofoxygen and nutrients from the surrounding tissues, and vascular
density at the tumor periphery is much greater than at the tumor
core. This density may contribute to peripheral tumor cell survival
by permitting residual blood flow after vascular damage [14,15].
In this study, ATO treatment alone did not delay the progression
of tumor growth, as shown in Figure 5. Thus, potentiation of con-
ventional therapies by combination with VDA may be ideal.
Specifically, a combination of VDAs and cytotoxic agents would
be expected to take advantage of the effect of the former on endo-
thelial cells and of the latter on tumor cells. Among three different
sequences of administration to establish an appropriate combination
model in this study with ATO and irinotecan, twice weekly ATO
treatment after injection of irinotecan showed additive antitumor effect
compared to control and irinotecan alone therapy. Interestingly, the
other sequences of administration showed that the inhibitory effect
of tumor growth is similar or less than the irinotecan alone group. This
could be explained by vessel shutdown induced by the VDA given after
the cytotoxic compound caused trapping of the already present cyto-
toxic drug within the tumor; however, concomitant or advanced
ATO treatment impair irinotecan distribution in the tumor. So, as
expected with VDAs, it is advisable to avoid giving chemotherapy or
radiotherapy shortly after ATO administration.
In summary, our data demonstrated that ATO acts as a VDA by
means of microtubule depolymerization. It exhibits significant vascu-
lar shutdown activity in CT26 allograft model and enhances anti-
tumor activity when used in combination with another cytotoxic
chemotherapeutic agent.References
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